234 related articles for article (PubMed ID: 28040682)
1. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.
Casulo C; O'Connor O; Shustov A; Fanale M; Friedberg JW; Leonard JP; Kahl BS; Little RF; Pinter-Brown L; Advani R; Horwitz S
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 28040682
[TBL] [Abstract][Full Text] [Related]
2. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.
Bachow SH; O'Connor OA
Clin Adv Hematol Oncol; 2015 Dec; 13(12):837-46. PubMed ID: 27058850
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.
Laribi K; Alani M; Truong C; Baugier de Materre A
Oncologist; 2018 Sep; 23(9):1039-1053. PubMed ID: 29674443
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
7. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
[TBL] [Abstract][Full Text] [Related]
8. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
9. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
11. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.
Allen PB; Pro B
Curr Oncol Rep; 2020 Apr; 22(5):44. PubMed ID: 32297075
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD; Horwitz SM
Semin Hematol; 2021 Apr; 58(2):78-84. PubMed ID: 33906725
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies in peripheral T-cell lymphoma.
Mehta-Shah N
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):41-46. PubMed ID: 31808829
[TBL] [Abstract][Full Text] [Related]
14. PTCL therapies: a review of treatment and outline of novel therapies.
Khan N; Cheson BD
Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
[TBL] [Abstract][Full Text] [Related]
15. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
Ong SY; Zain JM
Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies in peripheral T cell lymphoma.
Jagadeesh D; Smith MR
Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
18. Molecular underpinning of extranodal NK/T-cell lymphoma.
Huang Y; de Leval L; Gaulard P
Best Pract Res Clin Haematol; 2013 Mar; 26(1):57-74. PubMed ID: 23768641
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
Horwitz SM; Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Hoppe RT; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Lunning M; Nademanee A; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H; Porcu P
J Natl Compr Canc Netw; 2016 Sep; 14(9):1067-79. PubMed ID: 27587620
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T-cell lymphoma.
Foss FM; Zinzani PL; Vose JM; Gascoyne RD; Rosen ST; Tobinai K
Blood; 2011 Jun; 117(25):6756-67. PubMed ID: 21493798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
